- Details
- Brian Shuch joins Pedro Barata to discuss the recent results from ZIRCON, a phase 3 study of 89 Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ccRCC). There is an unmet need for an accurate noninvasive method for pre-treatment risk stratification in detecting renal masses. The trial evaluated the efficacy of the imaging agent desferrioxamine-zirconium-girentuximab (Teli...
|
- Details
- Gary Deng discusses his book "The Wellness Principles" in a conversation with Alicia Morgans. The book, which Dr. Deng describes as a wellness guide rather than a cookbook, is aimed at improving the quality of life for cancer patients by encouraging healthy lifestyles. Dr. Deng argues against extreme diet plans, instead promoting balanced, quick-to-make, and delicious meals. In particular, he shar...
|
- Details
- Pedro Barata is joined by Christopher Ryan to discuss SWOG S0931, the EVEREST trial of everolimus as adjuvant therapy for patients with renal cell carcinoma (RCC). The authors designed a phase III, double-blind, placebo-controlled, intergroup study of the mTOR inhibitor everolimus as adjuvant therapy following resection of RCC. Everolimus is an mTOR inhibitor that is FDA-approved for treating adva...
|
- Details
- Deepak Kilari joins Pedro Barata in a discussion on the ORACLE study, which investigates the efficacy of combination systemic therapies in patients with advanced non-clear cell renal cell carcinoma. Dr. Kilari gives an overview of the trial design and shares his hopes and goals for the future of this trial as it continues to expand to more institutions and provide a larger, more robust data set. B...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Lancet publication Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Approximately 80% of patients, present initially with local regional disease. However, despite the i...
|
- Details
- Sarmad Sadeghi and Pedro Barata discuss the results of a randomized Phase II that explored OX40in combination with axitinib in patients with renal cell carcinoma. Patients in the trial had progressive disease after receiving immunotherapy with the usual PD-1/PD-L1 antibodies. The primary endpoint was progression-free survival. Dr. Sadeghi describes the rationale for the trial design, why the trial...
|
- Details
- Laurence Albiges joins Pedro Barata highlighting the phase 2 KEYNOTE-B61 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). This is an area of unmet need and during the ESMO 2022 meeting, Dr. Albiges presented study data for the first time. KEYNOTE-B61 enroll patients with non-clear cell histology that have never been pre...
|
- Details
- Ralph Clayman converses with Jaime Landman about the controversial practice of biopsying renal masses, a topic that has stirred significant debate within the medical community. Dr. Landman elucidates the merits of Biopsy Informed Active Surveillance (BIAS), a departure from the existing renal mass guidelines that he argues are largely culture-based rather than data-driven. Dr. Landman highlights t...
|
- Details
- Monty Pal and Jaime Landman discuss Landman's groundbreaking article on office-based renal mass biopsies. Dr. Landman elaborates on his decade-long journey to develop the technique, similar to prostate biopsies, that can significantly impact kidney cancer treatment decisions. He shares results from a multicenter trial involving 72 patients, demonstrating the feasibility and benefits of office-base...
|
- Details
- In this episode of Kidney Cancer Today, Monty Pal and Jamie Landman team up with Laura Bukavina and Lee Ponsky to discuss consults for benign renal cysts undergoing unnecessary active surveillance. Among other topics, their conversation especially touches on present flaws in the healthcare system, including the appropriate evaluation of renal cysts and healthcare disparities in accessibility to ac...
|
